产品
编 号：F196192
分子式：C18H21NO6
分子量：347.36
分子式：C18H21NO6
分子量：347.36
产品类型
规格
价格
是否有货
结构图
CAS No: 163133-43-5
产品详情
生物活性：
Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs). Naproxcinod shows analgesic and anti-inflammatory effects, it can be used for the research of osteoarthritis and inflammation.
体内研究：
Naproxcinod (0-41 mg/kg; p.o. once daily for 42 weeks) shows a significantly higher mean BW (7.3%) than vehicle group and improves skeletal and cardiac disease phenotype in the mouse model of DMD.Animal Model:C57BL/10 mice with Duchenne muscular dystrophy (DMD)
Dosage:0, 10, 21 and 41 mg/kg
Administration:Oral gavage; 0-41 mg/kg once daily for 42 weeks
Result:Significantly improved fraction shortening and ejection fraction, and reduced inflammation in vivo.
体外研究：
Naproxcinod (1-30 μM; 15 min) concentration-dependently increases cGMP level up to 27-fold over basal level.Naproxcinod (1-100 μM; 8 h) concentration-dependently increases HO-1 mRNA in endothelial cells.
Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs). Naproxcinod shows analgesic and anti-inflammatory effects, it can be used for the research of osteoarthritis and inflammation.
体内研究：
Naproxcinod (0-41 mg/kg; p.o. once daily for 42 weeks) shows a significantly higher mean BW (7.3%) than vehicle group and improves skeletal and cardiac disease phenotype in the mouse model of DMD.Animal Model:C57BL/10 mice with Duchenne muscular dystrophy (DMD)
Dosage:0, 10, 21 and 41 mg/kg
Administration:Oral gavage; 0-41 mg/kg once daily for 42 weeks
Result:Significantly improved fraction shortening and ejection fraction, and reduced inflammation in vivo.
体外研究：
Naproxcinod (1-30 μM; 15 min) concentration-dependently increases cGMP level up to 27-fold over basal level.Naproxcinod (1-100 μM; 8 h) concentration-dependently increases HO-1 mRNA in endothelial cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备